[go: up one dir, main page]

WO2007025249A3 - Methodes de traitement des maux de tete par administration d'oxytocine - Google Patents

Methodes de traitement des maux de tete par administration d'oxytocine Download PDF

Info

Publication number
WO2007025249A3
WO2007025249A3 PCT/US2006/033500 US2006033500W WO2007025249A3 WO 2007025249 A3 WO2007025249 A3 WO 2007025249A3 US 2006033500 W US2006033500 W US 2006033500W WO 2007025249 A3 WO2007025249 A3 WO 2007025249A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
headaches
oxytocin
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/033500
Other languages
English (en)
Other versions
WO2007025249A2 (fr
Inventor
David C Yeomans
Martin S Angst
William H Frey
Daniel I Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CA002620364A priority Critical patent/CA2620364A1/fr
Priority to JP2008528234A priority patent/JP5276982B2/ja
Priority to DE602006012513T priority patent/DE602006012513D1/de
Priority to AU2006282799A priority patent/AU2006282799B2/en
Priority to EP06802456A priority patent/EP1928484B1/fr
Priority to AT06802456T priority patent/ATE458491T1/de
Publication of WO2007025249A2 publication Critical patent/WO2007025249A2/fr
Publication of WO2007025249A3 publication Critical patent/WO2007025249A3/fr
Priority to IL189777A priority patent/IL189777A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des méthodes de traitement des maux de tête et des troubles liés aux maux de tête. Lesdites méthodes consistent à administrer un peptide d'oxytocine pour le traitement de maux de tête primaires et secondaires ou de la névralgie faciale.
PCT/US2006/033500 2005-08-26 2006-08-28 Methodes de traitement des maux de tete par administration d'oxytocine Ceased WO2007025249A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002620364A CA2620364A1 (fr) 2005-08-26 2006-08-28 Methodes de traitement des maux de tete par administration d'oxytocine
JP2008528234A JP5276982B2 (ja) 2005-08-26 2006-08-28 オキシトシンの投与による頭痛の処置のための方法
DE602006012513T DE602006012513D1 (de) 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
AU2006282799A AU2006282799B2 (en) 2005-08-26 2006-08-28 Methods for treatment of headaches by administration of oxytocin
EP06802456A EP1928484B1 (fr) 2005-08-26 2006-08-28 Methodes de traitement des maux de tete par administration d'oxytocine
AT06802456T ATE458491T1 (de) 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
IL189777A IL189777A0 (en) 2005-08-26 2008-02-26 Method for treatment of headaches by administration of oxytocin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71195005P 2005-08-26 2005-08-26
US60/711,950 2005-08-26
US79400406P 2006-04-21 2006-04-21
US60/794,004 2006-04-21

Publications (2)

Publication Number Publication Date
WO2007025249A2 WO2007025249A2 (fr) 2007-03-01
WO2007025249A3 true WO2007025249A3 (fr) 2007-04-19

Family

ID=37654909

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/033500 Ceased WO2007025249A2 (fr) 2005-08-26 2006-08-28 Methodes de traitement des maux de tete par administration d'oxytocine
PCT/US2006/033672 Ceased WO2007025286A2 (fr) 2005-08-26 2006-08-28 Methode d'administration de medicaments pour traitement de la douleur trigeminale

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033672 Ceased WO2007025286A2 (fr) 2005-08-26 2006-08-28 Methode d'administration de medicaments pour traitement de la douleur trigeminale

Country Status (9)

Country Link
US (9) US20070093420A1 (fr)
EP (3) EP2056800B1 (fr)
JP (4) JP2009506076A (fr)
AT (1) ATE458491T1 (fr)
AU (1) AU2006282799B2 (fr)
CA (2) CA2620364A1 (fr)
DE (1) DE602006012513D1 (fr)
IL (1) IL189777A0 (fr)
WO (2) WO2007025249A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198240B2 (en) 2005-08-26 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US9629894B2 (en) 2015-01-07 2017-04-25 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
WO2007047583A2 (fr) 2005-10-18 2007-04-26 National Jewish Medical And Research Center Cellules souches a long terme immortalisees de façon conditionnelle et procedes de fabrication de ces cellules
RS57194B1 (sr) 2005-11-14 2018-07-31 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
WO2007120485A2 (fr) * 2006-03-30 2007-10-25 Cinergen, Llc Procédés de traitement de la douleur avec des alkylxanthines et des antiépileptiques et compositions à utiliser à cet effet
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2008112807A1 (fr) * 2007-03-12 2008-09-18 Sarentis Therapeutics, Inc. Analgésie topique de la cornée utilisant des agonistes des récepteurs de la neurotensine et des associations synergiques de neurotensine sans retarder la cicatrisation des plaies
EP2583550A1 (fr) * 2007-03-13 2013-04-24 National Jewish Health Procédés de génération d'anticorps
WO2008154337A1 (fr) * 2007-06-08 2008-12-18 Healthpartners Research Foundation Compositions pharmaceutiques et procédés permettant d'amplifier le ciblage de composés thérapeutiques sur le système nerveux central
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
WO2009012376A1 (fr) * 2007-07-17 2009-01-22 The Ohio State University Research Foundation Compositions et méthodes se rapportant aux soins de la peau
RU2010114040A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение дезлорелина и мастопана в качестве терапевтического средства
KR20100056509A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
WO2009033730A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratoires Ag Utilisation d'un peptide comme agent thérapeutique
WO2009033489A2 (fr) * 2007-09-11 2009-03-19 Glostrup Hospital Traitement de la migraine et de céphalées par des inhibiteurs sélectifs de pac1
WO2009033721A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide comme agent thérapeutique
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
US20110117106A1 (en) * 2008-03-06 2011-05-19 Alice Prince Uses of calpain inhibitors to inhibit inflammation
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
KR101803099B1 (ko) * 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
AU2009274172B2 (en) * 2008-07-21 2015-08-13 Htyr Acquisition Llc Differentiated anucleated cells and method for preparing the same
CN104353066B (zh) 2008-08-28 2017-05-10 泰加生物工艺学公司 Myc的调节剂、其使用方法和鉴别调节myc的试剂的方法
US20110178541A1 (en) * 2008-09-12 2011-07-21 Slender Medical, Ltd. Virtual ultrasonic scissors
WO2010029441A2 (fr) * 2008-09-15 2010-03-18 Optinose As Administration par voie nasale
AU2009305563C1 (en) 2008-10-17 2015-09-03 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US8575309B2 (en) 2008-12-08 2013-11-05 Biousian Biosystems, Inc. Delta-opioid receptor selective analgesics
EP3620154A1 (fr) 2009-02-06 2020-03-11 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
MX2011012043A (es) * 2009-05-13 2012-03-29 Protein Delivery Solutions Llc Sistema farmaceutico para suministro transmembrana.
US9107876B2 (en) 2009-07-02 2015-08-18 Yamaguchi University Surface anesthetic agent
EP2459183B1 (fr) 2009-07-27 2015-10-07 Nocicepta Llc Méthodes de traitement de la douleur
FR2948809B1 (fr) * 2009-07-31 2012-08-17 St Microelectronics Rousset Amplificateur de lecture faible puissance auto-minute
EP2470207A1 (fr) 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine
JP2013503862A (ja) 2009-09-08 2013-02-04 シグネーチャー セラピューティクス，インク． 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
US8622993B2 (en) * 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
US20130109674A1 (en) * 2009-12-18 2013-05-02 Achelios Therapeutics Llc Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US20110184322A1 (en) * 2010-01-22 2011-07-28 Slender Medical Ltd. Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
CN102892289B (zh) 2010-03-03 2015-03-25 尼昂克技术公司 包含单萜的药物组合物
WO2011133348A1 (fr) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprenant des promédicaments de type amphétamine clivables par enzyme et leurs inhibiteurs
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011133178A1 (fr) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprenant un promédicament de tapentadol modifié phénol clivable par enzyme
WO2011133179A1 (fr) * 2010-04-21 2011-10-27 Pharmacofore, Inc Composition comprenant un promédicament de type hydromorphone clivable par enzyme
US9242122B2 (en) 2010-05-14 2016-01-26 Liat Tsoref Reflectance-facilitated ultrasound treatment and monitoring
US8956346B2 (en) 2010-05-14 2015-02-17 Rainbow Medical, Ltd. Reflectance-facilitated ultrasound treatment and monitoring
US8617150B2 (en) 2010-05-14 2013-12-31 Liat Tsoref Reflectance-facilitated ultrasound treatment
US9101569B2 (en) 2010-05-18 2015-08-11 Universite De Geneve Methods for the treatment of insulin resistance
WO2012003968A1 (fr) * 2010-07-06 2012-01-12 Grünenthal GmbH Nouvelles formes posologiques à rétention gastrique comprenant un analogue de gaba et un opioïde
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP2609064B1 (fr) 2010-08-27 2016-09-28 Neonc Technologies Inc. Compositions pharmaceutiques comprenant des dérivés de l'alcool périllylique
GB201015371D0 (en) * 2010-09-14 2010-10-27 Optinose As Nasal delivery
US8647661B1 (en) * 2010-11-05 2014-02-11 Florida A&M University Surface modified multilayered nanostructures for dermal delivery
EP4374929B1 (fr) 2010-12-17 2025-09-03 University of Southern California Procédés et dispositifs d'utilisation d'alcool isoperillylique
WO2012096886A1 (fr) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions contenant un promédicament d'oxycodone pouvant être clivé par une enzyme
CN103384472B (zh) 2011-01-11 2016-01-20 特色疗法股份有限公司 包含酶可裂解的羟考酮药物前体的组合物
US20120183580A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic Composition for Transbuccal Administration
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10687975B2 (en) * 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
WO2012122420A2 (fr) 2011-03-09 2012-09-13 Pharmacofore, Inc. Promédicaments opioïdes présentant des groupes de liaison hétérocycliques
BR112013022946A2 (pt) 2011-03-09 2017-07-18 Signature Therapeutics Inc pró-fármacos de agentes ativos com ligantes heterocíclocos
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
PL2694050T3 (pl) * 2011-04-05 2020-03-31 Grünenthal GmbH Tapentadol do stosowania w leczeniu bólu związanego z nerwobólami nerwu trójdzielnego
DK2694049T3 (da) 2011-04-05 2019-01-02 Gruenenthal Gmbh Tapentadol til forebyggelse af kronificering af smerte
US20120277319A1 (en) 2011-04-29 2012-11-01 Gruenenthal Gmbh Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
WO2012174481A1 (fr) 2011-06-15 2012-12-20 Nerve Access, Inc. Compositions pharmaceutiques destinées à une administration intranasale pour le traitement de troubles neurodégénératifs
WO2013067309A1 (fr) * 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Procédés et compositions pour l'administration orale de composés agonistes d'un récepteur de la mélanocortine
US9468599B2 (en) * 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
EP2800606A4 (fr) * 2012-01-05 2015-07-15 Beech Tree Labs Inc Méthode de traitement de la douleur par administration de facteur de croissance du nerf
US9707414B2 (en) 2012-02-14 2017-07-18 Rainbow Medical Ltd. Reflectance-facilitated ultrasound treatment and monitoring
AU2013219799C1 (en) 2012-02-15 2017-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
DK2877189T3 (da) 2012-07-20 2021-02-22 Taiga Biotechnologies Inc Forbedret rekonstituering og autorekonstituering af det hæmopoietiske kammer
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
EP2914192B1 (fr) 2012-11-05 2019-05-01 Pythagoras Medical Ltd. Ablation commandée de tissu
JP6284541B2 (ja) * 2012-11-28 2018-02-28 ネクター セラピューティクス 長時間作用型トポイソメラーゼｉ阻害薬による乳癌治療の有効性を評価及び予測する方法
US9050330B2 (en) * 2012-12-06 2015-06-09 Jose C. Ramon-de-Jesus Method, composition and kit for treating frequent headaches
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
US20140294923A1 (en) * 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9676851B2 (en) 2013-03-15 2017-06-13 Amgen Inc. Human PAC1 antibodies
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
HUE065397T2 (hu) 2014-03-21 2024-06-28 Teva Pharmaceuticals Int Gmbh Kalcitonin génekkel kapcsolatos peptid elleni antagonista antitestek és azokat alkalmazó eljárások
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN106659531A (zh) 2014-05-07 2017-05-10 毕达哥拉斯医疗有限公司 受控组织消融技术
EP3154533A4 (fr) * 2014-06-16 2018-01-10 Loewi LLC Procédés d'anesthésie de tissu nerveux dans la voie du nerf trijumeau et utilisations médicales de ceux-ci
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
ES2821822T3 (es) * 2014-10-01 2021-04-27 Oxytone Bioscience B V Unidad de dosificación farmacéutica sólida desintegrante por vía oral que contiene una sustancia de control de partos
PL3200773T3 (pl) * 2014-10-01 2018-12-31 Oxytone Bioscience B.V. Rozpadająca się w ustach stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród
ES2986830T3 (es) 2014-10-20 2024-11-12 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
CN107075588B (zh) 2014-10-21 2023-03-21 普梭梅根公司 用于微生物组来源的诊断和治疗的方法及系统
CN111921046B (zh) 2014-11-19 2022-07-22 奥普蒂诺斯公司 经鼻给药
EP3226972A4 (fr) * 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Méthodes et compositions pour le traitement de la migraine et d'états pathologiques associés à la douleur
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN112142749A (zh) 2015-02-12 2020-12-29 NeOnc技术股份有限公司 紫苏醇衍生物、药物组合物及其用途
JP6734258B2 (ja) * 2015-03-04 2020-08-05 栄研化学株式会社 オキシトシンの高感度測定法
JP6917899B2 (ja) 2015-04-16 2021-08-11 ハー・ルンドベック・アクチエゼルスカベット 抗ｐａｃａｐ抗体及びそれらの使用
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
MA43567A (fr) 2015-12-15 2018-11-14 Amgen Inc Anticorps pacap et leurs utilisations
CA3020179A1 (fr) 2016-04-12 2017-10-19 Trigemina, Inc. Formulations d'oxytocine contenant du magnesium et procedes d'utilisation
US10202435B2 (en) 2016-04-15 2019-02-12 Alder Biopharmaceuticals, Inc. Anti-PACAP antibodies and uses thereof
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
EP3687375A4 (fr) * 2016-11-21 2022-01-19 Psomagen, Inc. Procédé et système pour caractériser une affection liée à une céphalée
DK3547836T3 (da) 2016-11-30 2024-11-18 Univ Southern California Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
IL281425B (en) 2016-12-02 2022-07-01 Taiga Biotechnologies Inc Nanoparticle formulations
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
CA3056239C (fr) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Promedicaments d'opioides a sous-unites multiples resistants aux surdoses et aux abus
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
AU2018335752B2 (en) 2017-09-22 2025-04-10 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
US10738110B2 (en) 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
WO2019157195A1 (fr) 2018-02-08 2019-08-15 Neonc Technologies, Inc Procédés de perméabilisation de la barrière hémato-encéphalique
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
WO2020182322A1 (fr) 2019-03-14 2020-09-17 Om Pharma Sa Méthode de traitement et/ou de prévention de l'asthme, d'exacerbations de l'asthme, de l'asthme allergique et/ou d'états associés à un microbiote lié à des troubles respiratoires
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
WO2021016190A1 (fr) * 2019-07-19 2021-01-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions et méthodes de modulation de troubles d'utilisation de médicaments
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
US11241477B2 (en) * 2019-08-29 2022-02-08 New York University Oxytocin compositions for treatment of tinnitus
US20240100120A1 (en) * 2019-10-11 2024-03-28 Board Of Regents, The University Of Taxas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
WO2021151100A1 (fr) 2020-01-24 2021-07-29 Aim Immunotech Inc. Procédés, compositions et vaccins pour le traitement d'une infection virale
EP4192436A4 (fr) * 2020-08-10 2024-10-02 Ziropa, Inc. Compositions et procédés d'administration topique
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
EP4469074A1 (fr) * 2022-01-27 2024-12-04 Belnap Pharmaceuticals, LLC Méthodes de traitement mettant en oeuvre l'oxytocine
WO2024102741A2 (fr) * 2022-11-07 2024-05-16 AEON Biopharma, Inc. Compositions destinées à être utilisées dans le traitement de troubles de céphalées
WO2025064708A1 (fr) * 2023-09-22 2025-03-27 The George Washington University Compositions comprenant de l'oxytocine et méthodes de traitement de surdose d'opioïdes
WO2025199179A2 (fr) 2024-03-18 2025-09-25 Tonix Pharmaceuticals Holding Corp. Analogues peptidiques de l'oxytocine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021286A1 (fr) * 1993-03-19 1994-09-29 Fjellestad Paulsen Anne Composition destinee a l'administration orale de peptides
DE4312913A1 (de) * 1992-10-23 1994-10-13 Knauf Siegfried Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine
WO1998043660A1 (fr) * 1997-03-27 1998-10-08 Karolinska Innovations Ab Utilisation de substances a activite oxytocique pour la preparation de medicaments destines au traitement de syndromes douloureux psychosomatiques
US5859048A (en) * 1994-12-28 1999-01-12 Teikoku Hormone Mfg. Co., Ltd. Pharmaceutics for mucosal administration
EP1468690A1 (fr) * 2003-03-27 2004-10-20 Pantarhei Bioscience B.V. Utilization d' oestrogenes dans le traitement de la sterilite masculine

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413A (en) * 1849-05-01 Improved method of making wire-strengthened spoons
US464378A (en) * 1891-12-01 Toilet-paper holder
US2938891A (en) * 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) * 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US4213968A (en) * 1978-06-05 1980-07-22 Coy David Howard Enkephalin derivatives
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486441A (en) * 1982-12-03 1984-12-04 Merrell Toraude Et Compagnie Pseudotropyl halogeno-benzoates and their use in migraine treatment
ATE78158T1 (de) 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
ZA887658B (en) * 1987-10-15 1990-06-27 Syntex Inc Intranasal administration of polypeptides in powdered form
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
AU6909091A (en) * 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US6407061B1 (en) * 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9203769D0 (en) * 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
US6054462A (en) * 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
ATE247456T1 (de) * 1996-02-27 2003-09-15 Teijin Ltd Puderförmige zusammensetzung zur nasalen anwendung
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
AU2173400A (en) 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
WO2000033813A1 (fr) * 1998-12-09 2000-06-15 Chiron Corporation Apport d'agents neurotrophiques au systeme nerveux central
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
EE200100677A (et) * 1999-06-16 2003-02-17 Nastech Pharmaceutical Co., Inc. Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal
JP2001002589A (ja) * 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
JP2001089359A (ja) * 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
CA2325106A1 (fr) * 1999-12-06 2001-06-06 Stanley L. Gore Compositions et methodes permettant de liberer des agents actifs dans le cerveau
CA2393688A1 (fr) * 1999-12-09 2001-06-14 Chiron Corporation Procede d'administration de cytokine aux systeme nerveux central et systeme lymphatique
US6413499B1 (en) * 2000-01-06 2002-07-02 Bryan M. Clay Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
KR20030060771A (ko) * 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
AU2002211688A1 (en) * 2000-10-13 2002-04-29 Chiron Corporation Method for treating ischemic events affecting the central nervous system
US20070112052A9 (en) * 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
EP1370275B1 (fr) * 2001-03-23 2010-05-26 Albert Einstein College Of Medicine Of Yeshiva University Procedes permettant d'augmenter l'activite analgesique et d'attenuer les effets excitateurs indesirables d'agonistes opioides agissant de facon bimodale par inhibition du ganglioside gm1
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002086105A1 (fr) 2001-04-20 2002-10-31 Chiron Corporation Apport d'agents polynucleotides au systeme nerveux central
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
JP2005524649A (ja) 2002-02-25 2005-08-18 カイロン コーポレーション Ｍｃ４−ｒアゴニストの鼻腔内投与
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
WO2003089456A2 (fr) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs peptidiques de la proteine kinase c
AU2003229735A1 (en) 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
AU2003273247A1 (en) 2002-08-30 2004-03-19 Board Of Regents, The University Of Texas System Non-invasive methods to identify agents for treating pain
US7065445B2 (en) * 2002-11-27 2006-06-20 Mobilearia Vehicle passive alert system and method
WO2004062563A2 (fr) 2003-01-16 2004-07-29 Université de Lausanne Methodes de criblage d'agents therapeutiques utiles dans le traitement de troubles lies a l'oxytocine et a la vasopressine
CA2520655A1 (fr) 2003-04-08 2004-11-04 Biotempt, B.V. Composition comprenant des fragments d'hcg pour administration par voie mucosale et buccale
WO2004093145A2 (fr) * 2003-04-11 2004-10-28 Paratek Microwave, Inc. Element dielectrique a photodefinition accordable en tension et procede de fabrication de celui-ci
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
WO2005115370A2 (fr) 2004-04-23 2005-12-08 The Regents Of The University Of California Composes et procedes de traitement de la douleur non inflammatoire au moyen d'agonistes de pparalpha
EP1604655A1 (fr) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US20060188496A1 (en) * 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
KR101399911B1 (ko) * 2005-03-11 2014-06-19 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 옥트레오타이드의 방출 조절형 제형
US20060252685A1 (en) * 2005-05-04 2006-11-09 Gould Jeffrey D Treatment for sleep apnea
EP2056800B1 (fr) * 2005-08-26 2015-12-09 The Board Of Trustees Of The Leland Stanford Junior University Methode d'administration de medicaments pour traitement de la douleur trigeminale
CN101404174B (zh) * 2007-10-04 2010-06-09 威刚科技股份有限公司 电子信息储存装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312913A1 (de) * 1992-10-23 1994-10-13 Knauf Siegfried Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine
WO1994021286A1 (fr) * 1993-03-19 1994-09-29 Fjellestad Paulsen Anne Composition destinee a l'administration orale de peptides
US5859048A (en) * 1994-12-28 1999-01-12 Teikoku Hormone Mfg. Co., Ltd. Pharmaceutics for mucosal administration
WO1998043660A1 (fr) * 1997-03-27 1998-10-08 Karolinska Innovations Ab Utilisation de substances a activite oxytocique pour la preparation de medicaments destines au traitement de syndromes douloureux psychosomatiques
EP1468690A1 (fr) * 2003-03-27 2004-10-20 Pantarhei Bioscience B.V. Utilization d' oestrogenes dans le traitement de la sterilite masculine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PHILLIPS W J ET AL: "Relief of acute migraine headache with intravenous oxytocin: Report of two cases", JOURNAL OF PAIN AND PALLIATIVE CARE PHARMACOTHERAPY 27 JUL 2006 UNITED STATES, vol. 20, no. 3, 27 July 2006 (2006-07-27), pages 25 - 28, XP009078117, ISSN: 1536-0288 1536-0539 *
ZUBRZYCKA M ET AL: "Inhibition of trigemino-hypoglossal reflex in rats by oxytocin is mediated by mu and kappa opioid receptors", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1035, no. 1, 21 February 2005 (2005-02-21), pages 67 - 72, XP004750936, ISSN: 0006-8993 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198240B2 (en) 2005-08-26 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US8202838B2 (en) 2005-08-26 2012-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US8252745B2 (en) 2005-08-26 2012-08-28 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US8258096B2 (en) 2005-08-26 2012-09-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US8501691B2 (en) 2005-08-26 2013-08-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US9629894B2 (en) 2015-01-07 2017-04-25 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use

Also Published As

Publication number Publication date
AU2006282799A1 (en) 2007-03-01
WO2007025286A3 (fr) 2007-05-10
JP5276982B2 (ja) 2013-08-28
EP2056800B1 (fr) 2015-12-09
JP2009506076A (ja) 2009-02-12
US8252745B2 (en) 2012-08-28
ATE458491T1 (de) 2010-03-15
CA2620364A1 (fr) 2007-03-01
US8198240B2 (en) 2012-06-12
JP5670415B2 (ja) 2015-02-18
EP2056800A2 (fr) 2009-05-13
US20090181880A1 (en) 2009-07-16
US20070093420A1 (en) 2007-04-26
DE602006012513D1 (de) 2010-04-08
US8258096B2 (en) 2012-09-04
US20120028898A1 (en) 2012-02-02
WO2007025286A2 (fr) 2007-03-01
EP2179741B1 (fr) 2014-10-15
US20090317377A1 (en) 2009-12-24
US20090291900A1 (en) 2009-11-26
EP2179741A1 (fr) 2010-04-28
US20120322736A1 (en) 2012-12-20
WO2007025249A2 (fr) 2007-03-01
EP1928484B1 (fr) 2010-02-24
US8202838B2 (en) 2012-06-19
EP1928484A2 (fr) 2008-06-11
JP2013060464A (ja) 2013-04-04
CA2620202C (fr) 2016-10-04
CA2620202A1 (fr) 2007-03-01
AU2006282799B2 (en) 2012-11-29
US20100080797A1 (en) 2010-04-01
US20110250212A1 (en) 2011-10-13
US8501691B2 (en) 2013-08-06
US20070054843A1 (en) 2007-03-08
JP2012207046A (ja) 2012-10-25
JP2009506071A (ja) 2009-02-12
IL189777A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
WO2007025249A3 (fr) Methodes de traitement des maux de tete par administration d'oxytocine
WO2009036175A3 (fr) Inhibiteur de f1f0-atpase et procédés associés
WO2012054364A3 (fr) Diamines bicycliques utiles en tant qu'inhibiteurs des kinases janus
IL185731A0 (en) Purification of montelukast
WO2010151799A3 (fr) Composés de modulation des protéines de liaison à l'arn et applications associées
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2007146284A3 (fr) Thiénopyrimidines utiles en tant que modulateurs de canaux ioniques
WO2007095638A3 (fr) Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
WO2008033408A3 (fr) Procédés d'identification de composés qui modulent la signalisation cellulaire et procédés employant de tels composés
WO2011133875A3 (fr) Composés inhibiteurs de métalloenzyme
WO2007075895A3 (fr) Derives heterocycliques utilises comme modulateurs de canaux ioniques
WO2011022489A3 (fr) Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles
WO2007137303A3 (fr) Perméabilité de la barrière hémato-encéphalique
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
WO2008118332A3 (fr) Peptides hydrazido en tant qu'inhibiteurs de la protéase ns3 du hcv
WO2006004884A3 (fr) Processus et intermediaires utilises dans la preparation d'inhibiteurs de kinases heterocycliques fusionnees
MX2010002408A (es) Tapa para botella, ensamble de tapa y botella.
WO2008063849A3 (fr) Thérapie de la sclérose en plaque
WO2011082245A3 (fr) Composés inhibiteurs de métallo-enzyme
WO2012064943A3 (fr) Composés inhibiteurs de métalloenzymes
MY166889A (en) Inhibitors of nedd8-activating enzyme
WO2010011343A3 (fr) Procédés de traitement d’affections virales
WO2010033392A3 (fr) Méthodes et trousses pour traiter des troubles induits par une algie vasculaire de la face
DE602006016449D1 (fr)
WO2012058529A3 (fr) Composés inhibiteurs de métalloenzymes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2620364

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008528234

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 189777

Country of ref document: IL

Ref document number: 2006282799

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 566391

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006802456

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006282799

Country of ref document: AU

Date of ref document: 20060828

Kind code of ref document: A